Posted in: information

Global top 50 pharmaceutical companies announced:Pfizer topped the list, and 4 Chinese companies were listed

Pharmexec published the top 50 list of global pharmaceutical enterprises in 2022. The list is mainly ranked according to the sales revenue of prescription drugs of various pharmaceutical companies in fiscal year 2021. The data are from evaluatepharma, a global pharmaceutical market research institution. This is the 23rd consecutive release of the list.

Pfizer ascends to the top, new crown vaccine becomes the key

Compared with the previous list,The top ten changed a lotPfizerandRocheWherePfizerLeading the list with 72billion US dollars, and winning the championship for two consecutive yearsRoche,因为“老三驾马车”Avastin(贝伐珠单抗)andHerceptin(曲妥珠单抗)、Rituxan(利妥昔单抗)收入的大幅萎缩,排名下降到第5位。

Pfizer无疑是2021年最大赢家,其2021年处方药总营收720亿美元Where370亿美元来自新冠疫苗 Comirnaty,这也使其成为有史以来最畅销的药物,远远超出了药王Humira(2021年销售206.9亿美元),此外Pfizer在下一次的年度榜单中依然有希望登顶,目前于去年年底获得紧急批准的新冠口服药Paxlovid已在全球60多个国家上市,Pfizer预测Paxlovid 2022全年销售将达到220亿美元。

除了Pfizer,还有不少药企通过新冠疫苗/药物迎来销售大涨。其中,mRNA疫苗企业Moderna凭借新冠疫苗Spikevax首次上榜,排在第17名。Spikevax在2021年营收176.75亿美元,几乎是Moderna处方药收入(191.67亿美元)的全部来源。根据该公司2022年Q1财报,Spikevax第一季度营收59亿美元,预计2022年全年达到210亿美元。It is worth noting that,从8月1日开始,Spikevax在日本的营销授权将从Takeda转移到Moderna。

In terms of regenerant, based on the promotion of ronapreve, a monoclonal antibody drug used to prevent new crown symptoms, it jumped to 8th place and ranked 20th. The sales volume of ronapreve in 2021 was US $5.8 billion.

Other companies that have risen in the rankings due to the impact of the new crown vaccine/drug include:AstraZeneca, the revenue of adenovirus vector vaccine vaxzevria reached USD 3.917 billion, ranking up two places to No. 9;Gilead , the income of veklury was USD 5.56 billion, rising one place to 12th place;Johnson, the income of the new crown vaccine jnj-78436735 was US $2.385 billion, and the ranking remained unchanged, ranking 4th.

此外,GSK的新冠中and抗体Xevudy收入13.17亿美元,排名第10;默沙东的口服新冠药物Molnupiravir在一个多月时间内贡献了9.52亿美元,排名第7。武田跌出前10。

4 Chinese enterprises on the list

It is worth noting that,此次有4 Chinese enterprises on the list,分别为Hengrui medicine (32nd)、China biopharmaceutical(No. 40), Shanghai Pharmaceutical (No. 41), Shijiazhuang Pharmaceutical Group (No. 43)

Hengrui medicineIn 2021, the revenue of prescription drugs reached US $5.203 billion (about RMB 34.836 billion), ranking 32nd and advancing 6 places, which is the best achievement of Chinese pharmaceutical companies on the global Top50 list.截至目前,Hengrui medicine共有10款创新药获批上市,分别是艾瑞昔布片、阿帕替尼片、硫培非格司亭注射液、吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲波帕乙醇胺片、达尔西利片and恒格列净片。“抗肿瘤药”仍是恒瑞的营收主力,其营业收入为130.7亿,营收占比为50.7%,毛利率为90.7%。

The second isChina biopharmaceutical, its ranking has not changed.China biopharmaceutical发布的2021年年报显示公司全年收入约268.6亿元,同比增长约13.6%;归母净利润约146.1亿元,同比大幅增长约427.2%。2020年12月,China biopharmaceutical向科兴中维出资5.15亿美元,获得后者15.03%权益。在2021年年报中,China biopharmaceutical将科兴中维作为联营公司以权益法入账。China biopharmaceutical在年报中表示,由于个别联营公司业绩亮丽,联营公司及合营公司整体于年度内为本集团带来合计约136.31亿元的盈利贡献,并特别提到公司持股15.03%的北京科兴中维生物技术有限公司“表现尤为突出”。按照这一持股比例进行推算,The profit of ZTE Zhongwei in 2021 is about 90billion yuan。China biopharmaceutical财报同时显示,科兴中维的新冠疫苗已在超过60个国家、地区及国际组织获批紧急使用或附条件上市,并进入世界卫生组织紧急使用清单。截至2022年3月24日,全球累计供应28亿剂,累计接种超24亿剂,成为全球使用最广泛的新冠疫苗之一。

Shanghai PharmaceuticalandShiyao groupLast year, it was listed on the list, and this year’s rankings have all advanced by one place.2021年,Shanghai Pharmaceutical实现营业收入2158.24亿元,同比增长12.46%;其中,医药工业实现收入250.98亿元,同比增长5.71%;医药商业实现收入1907.26亿元,同比增长13.42%;研发投入25.03亿元,同比增长26.94%。2021年Shiyao group营收278.67亿元,同比增长11.7%。其中成药业务录收入226.81亿元,较去年增加11.2%。抗肿瘤产品收入77.11亿元首次反超神经系统药物。2021年研发投入再创新高,研发费用达34.33亿元,同比增加18.8%,预计未来五年将有30余个创新药及新型制剂产品,以及60余个仿制药上市。

In addition, it is worth mentioning that Yunnan Baiyao, which ranked 34th, fell out of the Top50 list last year.

Attached is the top 50 list of global pharmaceutical enterprises in 2021: